Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Finch Therapeutics Group (FNCH)
OTHER OTC:FNCH
Holding FNCH?
Track your performance easily
FNCH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $14.26
Previous CloseN/A
Volume338.00
Average Volume (3M)1.65K
Market Cap
$17.58M
Enterprise Value$12.98M
Total Cash (Recent Filing)$42.19M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding1,605,763
10 Day Avg. Volume560
30 Day Avg. Volume1,653
Standard Deviation1.03
R-Squared0.00360
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.72
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue6.47
Enterprise Value/Gross Profit121.27
Enterprise Value/Ebitda-0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Finch Therapeutics Group News
PremiumCompany Announcements
Finch Therapeutics Group to Delist from Nasdaq
PremiumCompany Announcements
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation
Options Prices
Currently, No data available
---
Ownership Overview
12.62% Insiders
0.47% Mutual Funds
1.32% Other Institutional Investors
85.59% Public Companies and
Individual Investors
FNCH FAQ
What was Finch Therapeutics Group’s price range in the past 12 months?
Finch Therapeutics Group lowest stock price was $0.80 and its highest was $14.26 in the past 12 months.
What is Finch Therapeutics Group’s market cap?
Finch Therapeutics Group’s market cap is $17.58M.
When is Finch Therapeutics Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Finch Therapeutics Group’s earnings last quarter?
Finch Therapeutics Group released its earnings results on Mar 28, 2024. The company reported -$1.894 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.894.
Is Finch Therapeutics Group overvalued?
According to Wall Street analysts Finch Therapeutics Group’s price is currently Overvalued.
Does Finch Therapeutics Group pay dividends?
Finch Therapeutics Group does not currently pay dividends.
What is Finch Therapeutics Group’s EPS estimate?
Finch Therapeutics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Finch Therapeutics Group have?
Finch Therapeutics Group has 1,605,763 shares outstanding.
What happened to Finch Therapeutics Group’s price movement after its last earnings report?
Finch Therapeutics Group reported an EPS of -$1.894 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of Finch Therapeutics Group?
Currently, no hedge funds are holding shares in FNCH
---
Company Description
Finch Therapeutics Group
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
---
Technical Analysis
Abeona Therapeutics
―
Adaptimmune Therapeutics
―
AlloVir
―
Bioxcel Therapeutics
―
Forte Biosciences
―
---